Search results
Sep 24, 2014 · A recent study found that false-positive elevations of carcinoembryonic antigen (CEA) in the range of 5 to 15 ng/mL were commonly found in patients under surveillance for disease recurrence after primary treatment for stages I to III colorectal cancer (CRC) (J Natl Compr Canc Netw. 2014;12:907-913).
CEA is typically reported in nanograms per milliliter (ng/mL). The reference range is 0-2.9 ng/mL of blood. Generally, healthcare providers consider typical CEA levels to be between 0 and 2.9 ng/mL. Research indicates that false-positive results are reported with concentrations as high as 35 ng/mL.
Jan 23, 2023 · Carcinoembryonic antigen (CEA) is a non-specific serum biomarker that is elevated in various malignancies such as colorectal cancer, medullary thyroid cancer, breast cancer, mucinous ovarian cancer, etc.
Oct 29, 2022 · There are also many benign (noncancerous) and inflammatory conditions that can increase CEA, leading to false positive results.
Dec 22, 2021 · Since serum carcinoembryonic antigen (CEA) can be falsely elevated in non-malignant conditions such as chronic obstructive pulmonary disease, peptic ulcer disease, gastritis, and diabetes, it is generally considered nondiagnostic [1,2]. However, CEA levels can be used to monitor disease response to therapy if elevated pre-treatment.
Abstract. Routine monitoring of carcinoembryonic antigen (CEA) levels is stan-dard in patients with resected colorectal cancer (CRC). The incidence of false-positives and the upper limits of false-positive elevations have not been previously well characterized.
The false-positive rates of CEA according to level were as follows: 5.1–10.0 ng/mL, 99.5%; 10.1–15.0 ng/mL, 87.2%; 15.1–20.0 ng/mL, 100.0%; > 20.0 ng/mL, 33.3%. A subsequent decrease in the...
